180 Life Sciences Corp.
ATNF
$1.04
-$0.01-0.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.56% | -410.76% | -7,190.68% | 101.10% | 12.83% |
| Total Depreciation and Amortization | -- | -122.30% | -42.08% | 1.69% | 3.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -79.49% | 13,639.42% | 84.58% | -157.09% | -54.54% |
| Change in Net Operating Assets | 83.97% | -17.77% | -24.97% | 469.71% | 84.85% |
| Cash from Operations | 10.20% | -324.99% | -130.76% | 170.37% | 52.16% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 98.99% | 31.19% | -79.73% | 0.00% | 2.68% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -99.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.07% | 1,159.25% | -79.73% | -0.19% | -118.01% |
| Foreign Exchange rate Adjustments | -101.21% | 218.36% | -3,245.00% | 500.00% | -140.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -119.60% | 561.45% | -302.30% | 136.18% | -89.28% |